States With Age Restriction On OTC DXM Sales Number 17 – And Counting
Executive Summary
Pennsylvania is 17th US state to limit sales of dextromethorphan OTCs to consumers 18 and older because teenagers' abuse of the ingredient for intoxicating effect remains a common problem.
You may also be interested in...
Two States Require Industry To Pay For Ongoing Drug Take-Back Programs
Consumer Healthcare Products Association looks to stem expansion of state-mandated drug take-back programs with programs that use existing facilities and infrastucture and don't require industry funidng, says state affairs VP Carlos Gutierrez. State bills limiting sales of DXM to minors and expansion of the NPLEx system to track PSE sales also are on CHPA’s radar.
States’ Limits On OTC Dextromethorphan Sales Could Force Congress’ Hand
US House legislation banning the sale of DXM OTCs to consumers under age 18 likely stands the same chance right now as previous versions that have failed, but CHPA expects an increasing number of state laws could spur future action.
NPLEx Brings A ‘Quiet’ Year On State PSE Legislation – CHPA
CHPA President and CEO Scott Melville says 2015 is the “quietest” in five years for state legislation on the sale of pseudoephedrine, a testament to NPLEx. Bills for Rx-only PSE sales introduced in four states this year failed.